Australie - anglais - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 1 mg - capsule, modified release - excipient ingredients: hypromellose; iron oxide yellow; gelatin; sodium lauryl sulfate; titanium dioxide; ethylcellulose; iron oxide red; magnesium stearate; lactose monohydrate; hyprolose; butan-1-ol; purified water; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - prograf-xl is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 0.5 mg - capsule, modified release - excipient ingredients: iron oxide yellow; hypromellose; iron oxide red; titanium dioxide; lactose monohydrate; ethylcellulose; magnesium stearate; sodium lauryl sulfate; gelatin; hyprolose; butan-1-ol; purified water; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - prograf-xl is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tobramycin, quantity: 80 mg - injection, solution - excipient ingredients: sodium hydroxide; sodium metabisulfite; phenol; water for injections; sulfuric acid; disodium edetate - for the treatment of serious infections of the following type where they are caused by susceptible organisms: skin and skin structure infections including burns, bone infections; gastrointestinal infections including peritonitis; central nervous system infections including meningitis, septicaemia and neonatal sepsis; lower respiratory tract infections including pneumonia, bronchopneumonia, and acute bronchitis; complicated and recurrent urinary tract infections such as pyelonephritis and cystitis.,aminoglycosides, including tobramycin, should not be used in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to other less toxic antibiotics.,tobramycin can be used in serious staphylococcal infections for which penicillin or other less toxic drugs are contraindicated and where susceptibility testing and clinical judgement indicate its use. if susceptibility tests show a resistance to tobramycin in the causative organisms other appropriate therapy should be instituted.,note that bacterial cultures should bo obtained before and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. if the organisms are resistant, other appropriate therapy should be instituted. in patients in whom gram-negative septicaemia, neonatal sepsis or meningitis is suspected, including those in whom concurrent therapy with a penicillin or cefalosporin and an aminoglycoside may be indicated, tobramycin therapy may be initiated before results of susceptibility studies are obtained. the decision to continue tobramycin therapy should be based upon the results of susceptibility studies, the severity of infection and the important additional concepts discussed in the product information leaflet.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - gefitinib, quantity: 250 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; povidone; sodium lauryl sulfate; magnesium stearate; lactose monohydrate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - treatment of patients with locally advanced or metastatic non small cell lung cancer (nsclc) whose tumours express activating mutations of the egfr tyrosine kinase.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

nature's sunshine products of australia pty ltd - passiflora incarnata, quantity: 100 mg; hypericum perforatum, quantity: 300 mg (equivalent: hypericum perforatum, qty 2.1 g) - capsule, hard - excipient ingredients: magnesium stearate; maltodextrin; silicon dioxide; potable water; glacial acetic acid; gelatin; sodium lauryl sulfate - traditionally used in western herbal medicine to decrease/reduce/relieve restlessness/excess nervous energy ; traditionally used in western herbal medicine to decrease/reduce/relieve nervous tension/unrest ; traditionally used in western herbal medicine to decrease/reduce/relieve symptoms of mild anxiety ; traditionally used in western herbal medicine to nervine/support nervous system ; traditionally used in western herbal medicine to soporific/induces sleep ; traditionally used in western herbal medicine to enhance/promote/increase healthy sleep patterns ; traditionally used in western herbal medicine to enhance/improve/promote/increase sleep quality/deep sleep

Australie - anglais - Department of Health (Therapeutic Goods Administration)

bausch & lomb australia pty ltd - tropicamide, quantity: 10 mg/ml - eye drops, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; purified water - to produce mydriasis and cycloplegia.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

bausch & lomb australia pty ltd - tropicamide, quantity: 5 mg/ml - eye drops, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; purified water - to produce mydriasis and cycloplegia.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

bausch & lomb australia pty ltd - pilocarpine nitrate, quantity: 20 mg/ml - eye drops, solution - excipient ingredients: purified water - chronic non-congestive glaucoma and as a miotic for reversing the action of the weaker mydriatics.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

bausch & lomb australia pty ltd - phenylephrine hydrochloride, quantity: 100 mg/ml - eye drops, solution - excipient ingredients: sodium metabisulfite; disodium edetate; purified water - phenylephrine is a directly acting sympathomimetic agent used topically in the eye as a mydriatic. minims phenylephrine hydrochloride eye drops are indicated to dilate the pupil for diagnostic or therapeutic procedures.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

bausch & lomb australia pty ltd - lidocaine hydrochloride monohydrate, quantity: 40 mg/ml; fluorescein sodium, quantity: 2.5 mg/ml - eye drops, solution - excipient ingredients: purified water; hydrochloric acid; povidone - as a diagnostic stain and topical anaesthetic combined, minims lignocaine and fluorescein is intended primarily to facilitate goldmann applanation tonometry.